Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis

Layegh, P. and Rajabi, O. and Jafari, M. R. and Emamgholi Tabar Malekshah, P. and Moghiman, T. and Ashraf, H. and Salari, R. (2011) Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Journal of Parasitology Research, 2011.

[img] Text
Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.pdf

Download (581kB)
[img] Text
JPR2011-656523.pdf

Download (581kB)

Abstract

Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis. Aims. The efficacy of a topical liposomal amphotericin B formulation was compared with intralesional glucantime in the treatment of cutaneous leishmaniasis. Methods. From 110 patients, the randomly selected 50 received a topical liposomal formulation of amphotericin B into each lesion, 3-7 drops twice daily, according to the lesion's size and for 8 weeks. The other group of 60 patients received intralesional glucantime injection of 1-2mL once a week for the same period. The clinical responses and side effects of both groups were evaluated weekly during the treatment course. Results. Per-protocol analysis showed no statistically significant difference between the two groups (P=0.317, 95 confidence interval (CI)=1.610 (0.632-4.101)). Moreover, after intention-to-treat analysis, the same results were seen (P=0.650, 95 CI=0.1.91 (0.560-2.530)). Serious post treatment side effects were not observed in either group. Conclusions. Topical liposomal amphotericin B has the same efficacy as intralesional glucantime in the treatment of cutaneous leishmaniasis. Copyright © 2011 Pouran Layegh et al.

Item Type: Article
Additional Information: Cited By :31 Export Date: 16 February 2020 Correspondence Address: Layegh, P.; Research Center for Skin Diseases and Cutaneous Leishmaniasis, Ghaem Hospital Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; email: pouranlayegh@yahoo.com
Uncontrolled Keywords: amphotericin B lipid complex meglumine antimonate adult article controlled study drug efficacy drug formulation drug hypersensitivity drug response drug safety female human injection site edema injection site erythema major clinical study male priority journal pruritus randomized controlled trial skin leishmaniasis treatment outcome
Subjects: WR Dermatology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib7 lib7
Date Deposited: 25 Apr 2020 08:46
Last Modified: 25 Apr 2020 08:46
URI: http://eprints.mums.ac.ir/id/eprint/17043

Actions (login required)

View Item View Item